What is Ionis Pharmaceuticals's earnings per share (EPS)?

Ionis Pharmaceuticals (IONS) reported diluted earnings per share of $-2.38 for fiscal year 2025. This represents a 21.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ionis Pharmaceuticals Financials

IONS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Ionis Pharmaceuticals (IONS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IONS FY2025 2026-04-29

Ionis shows a research-heavy, asset-light revenue model where cash burn and external financing matter more than production costs.

From FY2024 to FY2025, cash burn improved faster than reported losses: operating cash outflow narrowed from -$500.9M to -$268.6M, a bigger shift than the net-loss improvement shown on the income statement. Yet financing inflow of $675.8M alongside 2.7x debt-to-equity shows FY2025 was still funded externally rather than by self-sustaining operations.

Gross margin near pure revenue at 98.3% says the business is not constrained by manufacturing or delivery cost. The economic drag sits in R&D intensity: FY2025 research spending of $915.6M almost matched revenue, so added sales still have to outrun a development budget that is running at near-revenue scale.

Short-term liquidity still exceeded near-term obligations, but the cushion thinned as the current ratio fell from 8.5x to 3.8x in one year. With $3.03B of liabilities and only $489.1M of equity, the balance sheet now has a much smaller equity buffer against continued losses, which helps explain why financing remains a recurring part of the model.

Financial Health Signals

Financial Health Score 56/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ionis Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

1.72

Ionis Pharmaceuticals scores 1.72, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($10.6B) relative to total liabilities ($3.0B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Ionis Pharmaceuticals passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.70x

For every $1 of reported earnings, Ionis Pharmaceuticals generates $0.70 in operating cash flow (-$268.6M OCF vs -$381.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-22.1x

Ionis Pharmaceuticals earns $-22.1 in operating income for every $1 of interest expense (-$381.7M vs $17.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$943.7M

YoY+33.8%

5Y CAGR+5.3%

10Y CAGR+12.8%

Ionis Pharmaceuticals generated $943.7M in revenue in fiscal year 2025. This represents an increase of 33.8% from the prior year.

EBITDA

-$369.2M

YoY+20.3%

Ionis Pharmaceuticals's EBITDA was -$369.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.3% from the prior year.

Net Income

-$381.4M

YoY+16.0%

Ionis Pharmaceuticals reported -$381.4M in net income in fiscal year 2025. This represents an increase of 16.0% from the prior year.

EPS (Diluted)

$-2.38

YoY+21.7%

Ionis Pharmaceuticals earned $-2.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 21.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$320.0M

YoY+41.4%

Ionis Pharmaceuticals generated -$320.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 41.4% from the prior year.

Cash & Debt

$372.3M

YoY+53.8%

5Y CAGR-1.3%

10Y CAGR+11.2%

Ionis Pharmaceuticals held $372.3M in cash against $1.3B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

163M

YoY+2.7%

5Y CAGR+3.1%

10Y CAGR+3.1%

Ionis Pharmaceuticals had 163M shares outstanding in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Margins & Returns

Gross Margin

98.3%

YoY-0.1pp

5Y CAGR-0.1pp

Ionis Pharmaceuticals's gross margin was 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.

Operating Margin

-40.5%

YoY+26.9pp

5Y CAGR-16.9pp

10Y CAGR-13.8pp

Ionis Pharmaceuticals's operating margin was -40.5% in fiscal year 2025, reflecting core business profitability. This is up 26.9 percentage points from the prior year.

Net Margin

-40.4%

YoY+24.0pp

5Y CAGR+20.5pp

10Y CAGR-9.3pp

Ionis Pharmaceuticals's net profit margin was -40.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 24.0 percentage points from the prior year.

Return on Equity

-78.0%

YoY-0.8pp

5Y CAGR-18.2pp

10Y CAGR-34.0pp

Ionis Pharmaceuticals's ROE was -78.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$915.6M

YoY+1.6%

5Y CAGR+11.5%

10Y CAGR+11.1%

Ionis Pharmaceuticals invested $915.6M in research and development in fiscal year 2025. This represents an increase of 1.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$51.4M

YoY+13.6%

5Y CAGR+7.9%

10Y CAGR+20.9%

Ionis Pharmaceuticals invested $51.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 13.6% from the prior year.

IONS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$943.7M+33.8%	$705.1M-10.5%	$787.6M+34.1%	$587.4M-27.5%	$810.5M+11.1%	$729.3M
Cost of Revenue	$15.9M+41.9%	$11.2M+22.8%	$9.1M-35.3%	$14.1M+30.2%	$10.8M-9.2%	$11.9M
Gross Profit	$927.8M+33.7%	$693.9M-10.9%	$778.5M+35.8%	$573.3M-28.3%	$799.6M+11.5%	$717.3M
R&D Expenses	$915.6M+1.6%	$901.5M+0.2%	$899.6M	N/A	$638.2M+20.2%	$531.0M
SG&A Expenses	$393.9M+47.3%	$267.5M+15.0%	$232.6M+54.8%	$150.3M-19.3%	$186.3M-47.4%	$354.3M
Operating Income	-$381.7M+19.7%	-$475.1M-34.3%	-$353.7M+13.8%	-$410.2M-1258.9%	-$30.2M+82.5%	-$172.1M
Interest Expense	$17.3M+1.6%	$17.0M+34.2%	$12.7M+55.9%	$8.1M-13.1%	$9.3M-1.7%	$9.5M
Income Tax	$1.8M+128.9%	-$6.2M-119.1%	$32.3M+175.4%	$11.7M+2230.1%	-$551K-100.2%	$345.2M
Net Income	-$381.4M+16.0%	-$453.9M-23.9%	-$366.3M-35.8%	-$269.7M-843.2%	-$28.6M+93.6%	-$444.3M
EPS (Diluted)	$-2.38+21.7%	$-3.04-18.8%	$-2.56-34.7%	$-1.90-850.0%	$-0.20+93.7%	$-3.18

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$246.1M+21.0%	$203.3M+29.7%	$156.7M-65.3%	$452.0M+243.5%	$131.6M-41.9%	$226.6M+69.3%	$133.8M-40.6%	$225.3M
Cost of Revenue	$3.0M	N/A	$2.3M-43.7%	$4.2M+183.7%	$1.5M	N/A	$1.1M-74.3%	$4.2M
Gross Profit	$243.1M	N/A	$154.4M-65.5%	$447.9M+244.1%	$130.1M	N/A	$132.7M-40.0%	$221.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$150.4M	N/A	$96.8M+6.8%	$90.6M+18.8%	$76.3M	N/A	$61.6M-5.3%	$65.1M
Operating Income	-$117.4M+45.2%	-$214.5M-33.9%	-$160.2M-214.6%	$139.8M+195.2%	-$146.9M-32.5%	-$110.8M+25.5%	-$148.7M-124.9%	-$66.1M
Interest Expense	$5.2M	N/A	$4.2M+2.4%	$4.1M+0.1%	$4.1M	N/A	$4.2M-7.3%	$4.5M
Income Tax	$218K	N/A	$213K+1165.0%	-$20K-117.2%	$116K	N/A	-$3.6M-5757.8%	$64K
Net Income	-$92.5M+59.7%	-$229.4M-78.4%	-$128.6M-204.1%	$123.6M+184.1%	-$146.9M-40.8%	-$104.3M+25.7%	-$140.5M-112.0%	-$66.3M
EPS (Diluted)	$-0.56+60.3%	$-1.41-76.2%	$-0.80-214.3%	$0.70+175.3%	$-0.93-40.9%	$-0.66+30.5%	$-0.95-111.1%	$-0.45

IONS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.5B+17.3%	$3.0B+0.5%	$3.0B+18.0%	$2.5B-3.0%	$2.6B+9.3%	$2.4B
Current Assets	$3.0B+14.1%	$2.6B-0.8%	$2.6B+19.9%	$2.2B-6.1%	$2.3B+10.1%	$2.1B
Cash & Equivalents	$372.3M+53.8%	$242.1M-39.4%	$399.3M+44.4%	$276.5M-68.2%	$869.2M+118.6%	$397.7M
Inventory	$10.0M-19.7%	$12.5M+68.1%	$7.4M-66.2%	$22.0M-11.2%	$24.8M+12.9%	$22.0M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.0B+25.6%	$2.4B-7.2%	$2.6B+32.8%	$2.0B+6.6%	$1.8B+11.8%	$1.6B
Current Liabilities	$781.6M+152.7%	$309.3M-31.0%	$448.1M+43.8%	$311.6M+29.5%	$240.6M-59.8%	$598.9M
Long-Term Debt	$1.3B+10.4%	$1.2B-3.1%	$1.2B+5.6%	$1.2B	N/A	$539.1M
Total Equity	$489.1M-16.9%	$588.4M+52.2%	$386.7M-32.5%	$572.9M-25.8%	$771.7M+3.8%	$743.3M
Retained Earnings	-$2.6B-17.0%	-$2.2B-25.3%	-$1.8B-25.6%	-$1.4B-23.3%	-$1.2B-2.5%	-$1.1B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$3.4B-2.1%	$3.5B+16.2%	$3.0B+1.6%	$3.0B+6.1%	$2.8B-6.3%	$3.0B-2.5%	$3.1B+14.5%	$2.7B
Current Assets	$2.9B-1.8%	$3.0B+18.7%	$2.5B-2.3%	$2.6B+6.5%	$2.4B-7.7%	$2.6B-3.4%	$2.7B+16.5%	$2.3B
Cash & Equivalents	$173.4M-53.4%	$372.3M+10.0%	$338.3M+13.8%	$297.3M+12.5%	$264.2M+9.1%	$242.1M-27.7%	$334.6M+13.8%	$294.0M
Inventory	$5.6M-44.7%	$10.0M-4.0%	$10.5M+23.5%	$8.5M-26.3%	$11.5M-8.1%	$12.5M-56.0%	$28.5M-0.9%	$28.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.0B-2.5%	$3.0B+25.7%	$2.4B+2.6%	$2.4B+0.7%	$2.3B-3.2%	$2.4B-0.1%	$2.4B-0.4%	$2.4B
Current Liabilities	$716.6M-8.3%	$781.6M-13.5%	$903.5M+0.7%	$897.2M+258.5%	$250.3M-19.1%	$309.3M+1.6%	$304.6M-0.5%	$306.2M
Long-Term Debt	N/A	$1.3B	N/A	N/A	N/A	$1.2B	N/A	N/A
Total Equity	$491.4M+0.5%	$489.1M-20.9%	$618.0M-2.2%	$631.7M+32.8%	$475.7M-19.1%	$588.4M-11.2%	$662.5M+151.2%	$263.7M
Retained Earnings	-$2.7B-3.5%	-$2.6B-9.6%	-$2.4B-5.7%	-$2.3B+5.2%	-$2.4B-6.5%	-$2.2B-4.9%	-$2.1B-7.0%	-$2.0B

IONS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$268.6M+46.4%	-$500.9M-62.9%	-$307.5M-12.1%	-$274.4M-990.8%	$30.8M-14.2%	$35.9M
Capital Expenditures	$51.4M+13.6%	$45.3M+90.2%	$23.8M+51.4%	$15.7M+31.5%	$12.0M-66.0%	$35.1M
Free Cash Flow	-$320.0M+41.4%	-$546.2M-64.9%	-$331.3M-14.2%	-$290.1M-1639.4%	$18.8M+2340.9%	$772K
Investing Cash Flow	-$277.8M-107.3%	-$134.0M+37.4%	-$214.1M+18.5%	-$262.6M-234.8%	$194.9M-29.0%	$274.5M
Financing Cash Flow	$675.8M+41.4%	$478.1M-25.8%	$644.1M+1264.8%	-$55.3M-122.5%	$245.9M+141.2%	-$596.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0-100.0%	$90.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$792.8M-475.7%	-$137.7M-4.8%	-$131.4M-186.8%	$151.3M+200.4%	-$150.8M-29.8%	-$116.1M-1.0%	-$115.0M+4.1%	-$119.9M
Capital Expenditures	$21.8M+2.2%	$21.3M+304.0%	$5.3M-57.2%	$12.3M-2.2%	$12.6M-50.7%	$25.5M+181.5%	$9.1M+45.3%	$6.2M
Free Cash Flow	-$814.6M-412.3%	-$159.0M-16.3%	-$136.7M-198.3%	$139.0M+185.1%	-$163.4M-15.3%	-$141.6M-14.2%	-$124.0M+1.6%	-$126.1M
Investing Cash Flow	$536.8M+228.0%	-$419.5M-559.3%	$91.3M+176.1%	-$120.1M-170.4%	$170.5M+149.9%	$68.2M+120.0%	-$340.8M-645.7%	$62.5M
Financing Cash Flow	$57.3M-90.3%	$591.2M+627.9%	$81.2M+6413.1%	$1.2M-43.3%	$2.2M+105.0%	-$44.1M-108.9%	$496.0M+19299.6%	$2.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IONS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	98.3%-0.1pp	98.4%-0.4pp	98.8%+1.2pp	97.6%-1.1pp	98.7%+0.3pp	98.4%
Operating Margin	-40.5%+26.9pp	-67.4%-22.5pp	-44.9%+24.9pp	-69.8%-66.1pp	-3.7%+19.9pp	-23.6%
Net Margin	-40.4%+24.0pp	-64.4%-17.9pp	-46.5%-0.6pp	-45.9%-42.4pp	-3.5%+57.4pp	-60.9%
Return on Equity	-78.0%-0.8pp	-77.1%+17.6pp	-94.7%-47.6pp	-47.1%-43.4pp	-3.7%+56.1pp	-59.8%
Return on Assets	-10.8%+4.3pp	-15.1%-2.9pp	-12.3%-1.6pp	-10.6%-9.6pp	-1.1%+17.5pp	-18.6%
Current Ratio	3.83-4.6	8.47+2.6	5.90-1.2	7.07-2.7	9.75+6.2	3.56
Debt-to-Equity	2.72+0.7	2.04-1.2	3.21+1.2	2.05-0.3	2.38+1.7	0.73
FCF Margin	-33.9%+43.5pp	-77.5%-35.4pp	-42.1%+7.3pp	-49.4%-51.7pp	2.3%+2.2pp	0.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	98.8%	N/A	98.5%-0.6pp	99.1%+0.2pp	98.9%	N/A	99.2%+1.0pp	98.2%
Operating Margin	-47.7%+57.7pp	-105.5%-3.3pp	-102.2%-133.1pp	30.9%+142.5pp	-111.6%-62.7pp	-48.9%+62.2pp	-111.1%-81.8pp	-29.3%
Net Margin	-37.6%+75.2pp	-112.8%-30.8pp	-82.1%-109.4pp	27.3%+139.0pp	-111.6%-65.6pp	-46.1%+58.9pp	-105.0%-75.6pp	-29.4%
Return on Equity	-18.8%+28.1pp	-46.9%-26.1pp	-20.8%-40.4pp	19.6%+50.4pp	-30.9%-13.2pp	-17.7%+3.5pp	-21.2%+3.9pp	-25.1%
Return on Assets	-2.7%+3.8pp	-6.5%-2.3pp	-4.2%-8.4pp	4.1%+9.4pp	-5.2%-1.8pp	-3.5%+1.1pp	-4.6%-2.1pp	-2.5%
Current Ratio	4.10+0.3	3.83+1.0	2.79-0.1	2.87-6.8	9.66+1.2	8.47-0.4	8.91+1.3	7.61
Debt-to-Equity	6.02+3.3	2.72-1.2	3.91+0.2	3.73-1.2	4.91+2.9	2.04-1.6	3.65-5.6	9.21
FCF Margin	-331.0%-252.8pp	-78.2%+9.0pp	-87.2%-118.0pp	30.8%+154.9pp	-124.1%-61.6pp	-62.5%+30.2pp	-92.7%-36.7pp	-56.0%

Similar Companies

Biomarin Pharmaceutical Inc BMRN

$11.5B

Exelixis Inc EXEL

$14.1B

Bridgebio Pharma BBIO

$15.3B

Ascendis Pharma ASND

$18.2B

Summit Therapeutics Inc SMMT

$12.2B

Frequently Asked Questions

What is Ionis Pharmaceuticals's annual revenue?

Ionis Pharmaceuticals (IONS) reported $943.7M in total revenue for fiscal year 2025. This represents a 33.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ionis Pharmaceuticals's revenue growing?

Ionis Pharmaceuticals (IONS) revenue grew by 33.8% year-over-year, from $705.1M to $943.7M in fiscal year 2025.

Is Ionis Pharmaceuticals profitable?

No, Ionis Pharmaceuticals (IONS) reported a net income of -$381.4M in fiscal year 2025, with a net profit margin of -40.4%.

What is Ionis Pharmaceuticals's EBITDA?

Ionis Pharmaceuticals (IONS) had EBITDA of -$369.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Ionis Pharmaceuticals have?

As of fiscal year 2025, Ionis Pharmaceuticals (IONS) had $372.3M in cash and equivalents against $1.3B in long-term debt.

What is Ionis Pharmaceuticals's gross margin?

Ionis Pharmaceuticals (IONS) had a gross margin of 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ionis Pharmaceuticals's operating margin?

Ionis Pharmaceuticals (IONS) had an operating margin of -40.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ionis Pharmaceuticals's net profit margin?

Ionis Pharmaceuticals (IONS) had a net profit margin of -40.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ionis Pharmaceuticals's return on equity (ROE)?

Ionis Pharmaceuticals (IONS) has a return on equity of -78.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ionis Pharmaceuticals's free cash flow?

Ionis Pharmaceuticals (IONS) generated -$320.0M in free cash flow during fiscal year 2025. This represents a 41.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ionis Pharmaceuticals's operating cash flow?

Ionis Pharmaceuticals (IONS) generated -$268.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ionis Pharmaceuticals's total assets?

Ionis Pharmaceuticals (IONS) had $3.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ionis Pharmaceuticals's capital expenditures?

Ionis Pharmaceuticals (IONS) invested $51.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ionis Pharmaceuticals spend on research and development?

Ionis Pharmaceuticals (IONS) invested $915.6M in research and development during fiscal year 2025.

How many shares does Ionis Pharmaceuticals have outstanding?

Ionis Pharmaceuticals (IONS) had 163M shares outstanding as of fiscal year 2025.

What is Ionis Pharmaceuticals's current ratio?

Ionis Pharmaceuticals (IONS) had a current ratio of 3.83 as of fiscal year 2025, which is generally considered healthy.

What is Ionis Pharmaceuticals's debt-to-equity ratio?

Ionis Pharmaceuticals (IONS) had a debt-to-equity ratio of 2.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ionis Pharmaceuticals's return on assets (ROA)?

Ionis Pharmaceuticals (IONS) had a return on assets of -10.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ionis Pharmaceuticals's cash runway?

Based on fiscal year 2025 data, Ionis Pharmaceuticals (IONS) had $372.3M in cash against an annual operating cash burn of $268.6M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ionis Pharmaceuticals's Altman Z-Score?

Ionis Pharmaceuticals (IONS) has an Altman Z-Score of 1.72, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ionis Pharmaceuticals's Piotroski F-Score?

Ionis Pharmaceuticals (IONS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ionis Pharmaceuticals's earnings high quality?

Ionis Pharmaceuticals (IONS) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ionis Pharmaceuticals cover its interest payments?

Ionis Pharmaceuticals (IONS) has an interest coverage ratio of -22.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ionis Pharmaceuticals?

Ionis Pharmaceuticals (IONS) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.